TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03776773

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pollution exposure
Description: Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pollution exposure
Description: Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pollution exposure
Description: Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.
Study: NCT01498614

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Affect School and Basal body awareness
Description: Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
Study: NCT00548444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Vaccine. Dose: 1 x 10\^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.
Study: NCT01139450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0417
Description: Topical 0417 test product applied twice daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of 0417 test product
Description: Vehicle of 0417 test product applied twice daily for 4 weeks
Study: NCT00548444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Vaccine. Dose: 1 x 10\^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Vaccine. Dose: 1 x 10\^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterated glucose infusion
Description: 6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
Study: NCT00690807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10
Description: PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.
Study: NCT00548444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterated glucose infusion
Description: 6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
Study: NCT02995044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-180)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT01139450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Ointment 0.03%
Description: Reference product for 0417 test product. Apply twice daily for 4 weeks
Study: NCT01462721

Intervention type: DEVICE
Group type: OTHER
Intervention: eSVS® Mesh
Description: Patients with multi-vessel coronary artery disease who require saphenous vein graft (SVG) coronary artery bypass graft (CABG) surgery of the Right coronary Artery (RCA) and the Circumflex Artery (Cx) due to atherosclerotic coronary artery disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
Study: NCT03068273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time CGM data

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time CGM data
Study: NCT00494910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning Centered Group Psychotherapy
Description: this eight-week (1 ½ hour weekly sessions) Session 1 - Concepts of Meaning and Sources of Meaning Session 2 - Cancer and Meaning Session 3 - Meaning and Historical Context of Life Session 4 - Storytelling, Legacy Project (optional) Session 5 - Limitations and Finiteness of Life Session 6 - Responsibility, Creativity, Deeds Session 7 - Experience, Nature, Art, Humor Session 8 - Transitions, Goodbyes, Hopes for the Future

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Group Psychotherapy
Description: The eight weekly 1 ½ hour sessions will focus on group discussion on a set of specific themes that emerge for patients coping with cancer. The session themes or topics will include such issues as: the discussion of strategies for coping with medical issues and procedures, communication with health care providers and issues related to family, friends, and occupational life.
Study: NCT01211366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell Saver RBCs
Description: Use of cell saver RBCs to decrease the infusion of allogeneic PRBCs, crystalloid, and colloid in post-operative infants following CPB as needed for hemodynamic instability
Study: NCT04352855

Intervention type: DRUG
Intervention: Ceftolozane/tazobactam
Description: Administration
Study: NCT00966602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-809
Description: VX-809 capsule, once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: VX-770 tablet, once every 12 hours for 14 days
Study: NCT01211366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional volume infusion
Description: Infusion of allogeneic PRBCs, crystalloid, and colloid as needed for hemodynamic instability
Study: NCT03010358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00966602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-809 & VX-770
Description: VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study: NCT04022720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin Application
Description: Platelet Rich Fibrin application at first post-op visit.
Study: NCT04345575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PainCare VR
Description: Didactic content delivered in virtual reality to support participants in learning cognitive and behavioral self-management skills based on cognitive-based therapy, biofeedback, and mindfulness strategies for pain management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audio content
Description: The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the VR program could not be included in the audio. Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
Study: NCT01763437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
Study: NCT02478658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: high-intensity resistance training
Study: NCT00784836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG9418 (interferon beta 1-a)
Study: NCT03943394

Intervention type: OTHER
Intervention: fresh samples are obtained from patients for detction of PCM1- JAK2 fusion gene
Description: Samples are dehydrated in ethanol (a 50, 80 and 95% (v/v) series, exposure for 3 min to 300 µl ethanol at each concentration) prior to hybridization.~Samples on tapes are hybridized for 15 minutes at 55?C using a moisture-sealed slide incubation chamber. Briefly, 500 µl volumes of hybridization buffer (0.7 M NaCl, 0.1 M Tris \[pH 8.0\], 0.1% sodium dodecyl sulfate, 10 mM EDTA, containing probe, preheated to 55 ºC) are applied to the surface of the tape and the chamber's lid is sealed, creating a moist, temperature controlled environment within the chamber.~After 15 min, the lid is removed and samples are briefly rinsed with probe-free hybridization buffer, preheated to 55ºC.~Hybridized cells on tapes are counterstained for 10 minutes in the dark with \~30 µl mounting medium containing 1.5 µg ml-1 4',6-diamidino-2-phenylindole (DAPI).~Then tapes are mounted with a coverslip and examined using a fluorescence microscope.

Intervention type: OTHER
Intervention: fresh samples are obtained from patients for detction of PCM1- JAK2 fusion gene
Description: Samples are dehydrated in ethanol (a 50, 80 and 95% (v/v) series, exposure for 3 min to 300 µl ethanol at each concentration) prior to hybridization.~Samples on tapes are hybridized for 15 minutes at 55?C using a moisture-sealed slide incubation chamber. Briefly, 500 µl volumes of hybridization buffer (0.7 M NaCl, 0.1 M Tris \[pH 8.0\], 0.1% sodium dodecyl sulfate, 10 mM EDTA, containing probe, preheated to 55 ºC) are applied to the surface of the tape and the chamber's lid is sealed, creating a moist, temperature controlled environment within the chamber.~After 15 min, the lid is removed and samples are briefly rinsed with probe-free hybridization buffer, preheated to 55ºC.~Hybridized cells on tapes are counterstained for 10 minutes in the dark with \~30 µl mounting medium containing 1.5 µg ml-1 4',6-diamidino-2-phenylindole (DAPI).~Then tapes are mounted with a coverslip and examined using a fluorescence microscope.
Study: NCT02320591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care management fee
Description: for each Medicare beneficiary attributed to the practice, the practice received a monthly care management fee
Study: NCT01908257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 400 mg
Study: NCT02320591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: feedback reports
Description: Each participating practice received quarterly reports showing the practice's trend in key outcomes during the pre-intervention and intervention periods. The risk adjusted average Medicare expenditures of their patients were also shown in relation to all of the other CPC practices in their region, and to those with a similar average risk profile. Unadjusted hospitalization rates and emergency room visits were also plotted over time and compared to those of other CPC practices in the region

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: technical assistance
Description: CPC practices could ask for technical assistance on transformation activities from a regional learning faculty (RLF). The RLF also provided seminars and other learning activities, as well as provided a forum for participating practices to share lessons they had learned.
Study: NCT00464126

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% albumin
Description: 5% albumin in 10cc/kg aliquots for postoperative volume resuscitation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: crystalloid
Description: saline in 10cc/kg aliquots for postoperative volume resuscitation
Study: NCT02892591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: vaporized plant material
Study: NCT06405256

Intervention type: RADIATION
Intervention: magnetic resonance imaging-guided adaptive radiotherapy
Description: Stereotactic Radiotherapy (with the prescribed dose of PTV 52-52.5 Gy, 13-15 fractions and Boost (if any) 60Gy, 15 fractions)
Study: NCT03859115

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TENS (transcutaneous electrical nerve stimulation)
Description: transcutaneous nerve stimulation with electrical pulse generation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electrical nerve stimulation)
Description: transcutaneous nerve stimulation with electrical pulse generation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electrical nerve stimulation)
Description: transcutaneous nerve stimulation with electrical pulse generation
Study: NCT02892591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: oral capsule
Study: NCT03859115

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: sham stimulation without electrical pulse generation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sham intervention
Description: sham stimulation without electrical pulse generation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sham intervention
Description: sham stimulation without electrical pulse generation
Study: NCT01226186

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse dispensed oral morphine.
Description: Nurse will dispense oral morphine on request from the patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient self medication of oral morphine.
Description: Patients will self medicate their oral morphine pain control solution following surgery.
Study: NCT04527627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Empowerment Intervention
Description: Nursing empowerment intervention The intervention will be carried out during the ICU discharge planning. A Patient Information Guide for Intensive Care Unit patients will be developed.~The guide will be based on the findings obtained in a previous qualitative study and on previous studies on patient empowerment and education. Its structure will take into account the dimensions of empowerment: bio-physiological, functional, social, experience, ethics and the financial aspect. The guide will be reviewed by experts in the development of information guides for patients and family members and will be evaluated by the participating ICUs before use.~EG patients will receive the intervention verbally and in booklet format from the study nurses at each ICU.
Study: NCT02636946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Description: Up to three Bimatoprost SR 15 micrograms (μg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 μg administrations at Day 4 and Week 16 (Stage 2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost SR
Description: Up to three Bimatoprost SR 15 micrograms (μg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 μg administrations at Day 4 and Week 16 (Stage 2).
Study: NCT04619563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride plus Docetaxel
Description: Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
Study: NCT03607435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectroscopy for Analyte Quantification
Description: Diabetic hospital staff participants subjected to the KBS-1 device (Test Article #01) will have a finger on their left hand pricked with a lancet and their blood glucose level read by a POC glucose monitor (Control Article #02). Next, they will have their interstitial fluid glucose level spectroscopically scanned from the palm of their left hand using the KBS-1 device, and blood (approximately 40µl), collected from their finger prick site, will be spectroscopically scanned using the RBA-1 device (Test Article #02). Hospital patients subjected to the RBA-1 device, who must already be prescribed a hospital lab blood test by their physician, will have approximately 40µl of their blood, collected from the venipuncture site, spectroscopically scanned using the RBA-1 device (Test Article #02).
Study: NCT01908257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg
Study: NCT02636946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Bimatoprost SR
Description: Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
Study: NCT02892591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Cannabis
Description: vaporized placebo plant material

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Cannabis
Description: vaporized placebo plant material

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oxycodone
Description: oral placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Oxycodone
Description: oral placebo capsule
Study: NCT01849536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish®
Study: NCT02636946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham Bimatoprost SR
Description: Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty
Description: Selective Laser Trabeculoplasty administered on Day 1.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser Trabeculoplasty
Description: Selective Laser Trabeculoplasty administered on Day 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Selective Laser Trabeculoplasty
Description: Sham Selective Laser Trabeculoplasty administered on Day 1.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Selective Laser Trabeculoplasty
Description: Sham Selective Laser Trabeculoplasty administered on Day 1.
Study: NCT00780273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankylos Implants
Description: ANKYLOS Implant System vs Certain PREVAIL Implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomet 3i Prevail Implants
Study: NCT02723474

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI at baseline and over time
Description: Hyperpolarized noble gas MRI has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI, Helium-3 and Xenon-129 gas is used as a contrast agent to directly visualize ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
Study: NCT02781038

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Subjects in this group will not receive the pamphlet
Study: NCT00306995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_15
Description: Non-adjuvanted pandemic influenza A formulation 1 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_8
Description: Non-adjuvanted pandemic influenza A formulation 2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_4
Description: Non-adjuvanted pandemic influenza A formulation 3 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_2
Description: Non-adjuvanted pandemic influenza A formulation 4 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_8AL
Description: Pandemic influenza A formulation 2 aluminium-adjuvanted vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_4AL
Description: Pandemic influenza A formulation 3 aluminium-adjuvanted vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_2AL
Description: Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine
Study: NCT03004339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 Ointment 2.0%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 Ointment 1.0%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 Ointment 0.3%
Study: NCT03479541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Participants will see a physiotherapist one-on-one twice per week for 2 weeks and once per week for 4 weeks for a total of 6 weeks. These sessions will consist of cardio, cervical flexion exercises and vestibule-ocular exercises for one hour. Participants will also have similar daily home exercises to complete for approximately 30 minutes. Both the one-on-one physiotherapy and home exercises will be individualized and progressive in the sense that each exercise can increase in the level of difficulty at the discretion of the physiotherapist depending on the performance of the participant.~For the group allocated to home monitoring, they will perform the vestibular exercises while wearing one wireless sensor on the head and one on the sternum. When the participant brings the sensors in to the physiotherapy session each week, the physiotherapist will examine the home data and likely make a more informed decision as to whether or not to increase the level of difficulty of the task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Participants will see a physiotherapist one-on-one twice per week for 2 weeks and once per week for 4 weeks for a total of 6 weeks. These sessions will consist of cardio, cervical flexion exercises and vestibule-ocular exercises for one hour. Participants will also have similar daily home exercises to complete for approximately 30 minutes. Both the one-on-one physiotherapy and home exercises will be individualized and progressive in the sense that each exercise can increase in the level of difficulty at the discretion of the physiotherapist depending on the performance of the participant.~For the group allocated to home monitoring, they will perform the vestibular exercises while wearing one wireless sensor on the head and one on the sternum. When the participant brings the sensors in to the physiotherapy session each week, the physiotherapist will examine the home data and likely make a more informed decision as to whether or not to increase the level of difficulty of the task.
Study: NCT00743041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Description: EFT is an exposure therapy with a cognitive component, consisting of recall of a trauma along with a statement of self-acceptance, in combination with touching or tapping on a series of stress reduction points on the body